300233 金城医药
已收盘 05-22 15:00:00
资讯
新帖
简况
金城医药（300233）披露参股公司VGX-3100中国III期临床揭盲达主要终点，5月20日股价下跌0.93%
证券之星 · 05-20 22:31
金城医药（300233）披露参股公司VGX-3100中国III期临床揭盲达主要终点，5月20日股价下跌0.93%
金城医药（300233）披露子公司收到化学原料药上市申请批准通知书，5月14日股价下跌3.36%
证券之星 · 05-14
金城医药（300233）披露子公司收到化学原料药上市申请批准通知书，5月14日股价下跌3.36%
金城医药最新公告：子公司收到戊酸雌二醇原料药上市申请批准通知书
证券之星 · 05-13
金城医药最新公告：子公司收到戊酸雌二醇原料药上市申请批准通知书
雾麻科技(ISPR.US)通过与山东金城医药集团成立合资公司进军尼古丁口含袋(Nicotine Pouch)市场
智通财经 · 05-12
雾麻科技(ISPR.US)通过与山东金城医药集团成立合资公司进军尼古丁口含袋(Nicotine Pouch)市场
雾麻科技携手金城医药成立战略合资公司，进军高增长尼古丁袋市场
美股速递 · 05-12
雾麻科技携手金城医药成立战略合资公司，进军高增长尼古丁袋市场
金城医药(300233)5月10日股东户数2.77万户，较上期减少1.38%
证券之星 · 05-12
金城医药(300233)5月10日股东户数2.77万户，较上期减少1.38%
金城医药：截至2026年5月10日，公司股东总户数为27,749户
证券之星 · 05-12
金城医药：截至2026年5月10日，公司股东总户数为27,749户
金城医药（300233）披露2025年年度权益分派实施公告，5月6日股价上涨2.64%
证券之星 · 05-06
金城医药（300233）披露2025年年度权益分派实施公告，5月6日股价上涨2.64%
金城医药：虾青素申报工作仍处于安全证书认证审评中
中金财经 · 04-29
金城医药：虾青素申报工作仍处于安全证书认证审评中
股市必读：金城医药一季报 - 第一季度单季净利润同比增长64.87%
证券之星 · 04-27
股市必读：金城医药一季报 - 第一季度单季净利润同比增长64.87%
金城医药(300233)4月20日股东户数2.97万户，较上期减少4.39%
证券之星 · 04-24
金城医药(300233)4月20日股东户数2.97万户，较上期减少4.39%
金城医药（300233）披露2026年一季度报告，4月23日股价上涨0.25%
中金财经 · 04-24
金城医药（300233）披露2026年一季度报告，4月23日股价上涨0.25%
金城医药(300233.SZ)发布一季度业绩，归母净利润5779.45万元，增长64.87%
智通财经 · 04-23
金城医药(300233.SZ)发布一季度业绩，归母净利润5779.45万元，增长64.87%
金城医药：截至2026年4月20日，公司股东总户数为29,730户
证券之星 · 04-23
金城医药：截至2026年4月20日，公司股东总户数为29,730户
金城医药：截至2026年4月10日公司股东总户数为31,096户
证券之星 · 04-16
金城医药：截至2026年4月10日公司股东总户数为31,096户
金城医药最新公告：子公司收到注射用乳糖酸红霉素药品注册证书
证券之星 · 04-10
金城医药最新公告：子公司收到注射用乳糖酸红霉素药品注册证书
股市必读：金城医药（300233）预计2026年1-3月扣非后净利润盈利4900万元至5900万元
证券之星 · 04-09
股市必读：金城医药（300233）预计2026年1-3月扣非后净利润盈利4900万元至5900万元
金城医药最新公告：预计一季度归母净利润同比增长51.19%—85.42%
证券之星 · 04-08
金城医药最新公告：预计一季度归母净利润同比增长51.19%—85.42%
金城医药：截至2026年3月31日，公司股东总户数为28,811户
证券之星 · 04-03
金城医药：截至2026年3月31日，公司股东总户数为28,811户
金城医药（300233）披露董事会专门委员会关于2025年度及换届相关事项的专门意见，3月30日股价下跌1.83%
证券之星 · 03-30
金城医药（300233）披露董事会专门委员会关于2025年度及换届相关事项的专门意见，3月30日股价下跌1.83%
加载更多
公司概况
公司名称：
山东金城医药集团股份有限公司
所属行业：
医药制造业
上市日期：
2011-06-22
主营业务：
山东金城医药集团股份有限公司的主营业务是医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售。公司的主要产品是硝呋太尔制霉素阴道软胶囊、硝呋太尔胶囊、普罗雌烯乳膏、普罗雌烯氯喹那多阴道片以及注射用头孢唑林钠、注射用头孢他啶、注射用头孢呋辛钠、头孢羟氨苄胶囊、头孢克洛分散片、烟碱、4-AA、4-BMA、EDC、DIC。金城医化、金城汇海通过工信部“绿色工厂”复审，金城医化、金城生物、金城柯瑞通过重点行业绩效分级B级复审。
发行价格：
18.60
{"stockData":{"symbol":"300233","market":"SZ","secType":"STK","nameCN":"金城医药","latestPrice":14.4,"timestamp":1779433431000,"preClose":14.58,"halted":0,"volume":8774400,"delay":0,"changeRate":-0.0123,"floatShares":370000000,"shares":384000000,"eps":0.1744,"marketStatus":"已收盘","change":-0.18,"latestTime":"05-22 15:00:00","open":14.67,"high":14.76,"low":14.2,"amount":126000000,"amplitude":0.0384,"askPrice":14.4,"askSize":105,"bidPrice":14.39,"bidSize":177,"shortable":0,"etf":0,"ttmEps":0.1744,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779672600000},"marketStatusCode":5,"adr":0,"adjPreClose":14.58,"symbolType":"stock","openAndCloseTimeList":[[1779413400000,1779420600000],[1779426000000,1779433200000]],"highLimit":16.04,"lowLimit":13.12,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":383874587,"isCdr":false,"pbRate":1.5,"roa":"--","peRate":82.568807,"roe":"1.57%","epsLYR":0.12,"committee":0.657186,"marketValue":5528000000,"turnoverRate":0.0237,"status":1,"floatMarketCap":5325000000},"requestUrl":"/m/hq/s/300233","defaultTab":"news","newsList":[{"id":"2636882539","title":"金城医药（300233）披露参股公司VGX-3100中国III期临床揭盲达主要终点，5月20日股价下跌0.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636882539","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636882539?lang=zh_cn&edition=full","pubTime":"2026-05-20 22:31","pubTimestamp":1779287476,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，金城医药报收于14.92元，较前一交易日下跌0.93%，最新总市值为57.27亿元。金城医药于近日披露《关于参股公司研发项目的进展公告》。公告显示，公司参股公司东方略生物研发的VGX-3100在中国III期关键性注册临床研究中已揭盲，主要疗效结果达到预设的主要终点，安全性良好，未发现新的重大安全风险。VGX-3100为针对HPV-16/18相关宫颈高级别鳞状上皮内病变的治疗性DNA疫苗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000043422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635718432","title":"金城医药（300233）披露子公司收到化学原料药上市申请批准通知书，5月14日股价下跌3.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635718432","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635718432?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:44","pubTimestamp":1778751865,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，金城医药报收于15.55元，较前一交易日下跌3.36%，最新总市值为59.69亿元。近日，山东金城医药集团股份有限公司全资子公司北京金城泰尔制药有限公司收到国家药品监督管理局下发的《化学原料药上市申请批准通知书》，批准其化学原料药戊酸雌二醇上市申请。该原料药用于治疗与绝经相关的雌激素缺乏，目前全球范围内2023年至2025年三季度消耗量及销售额有所波动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400032623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300233","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635009842","title":"金城医药最新公告：子公司收到戊酸雌二醇原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2635009842","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635009842?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:49","pubTimestamp":1778665760,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，公司全资子公司北京金城泰尔制药有限公司收到国家药监局下发的《化学原料药上市申请批准通知书》，批准戊酸雌二醇原料药注册。该药品主要用于补充与自然或人工绝经相关的雌激素缺乏。此次获批有利于丰富公司妇科产品线，提升市场竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300033039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634211236","title":"雾麻科技(ISPR.US)通过与山东金城医药集团成立合资公司进军尼古丁口含袋(Nicotine Pouch)市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2634211236","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634211236?lang=zh_cn&edition=full","pubTime":"2026-05-12 20:40","pubTimestamp":1778589639,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，雾麻科技今日宣布与全球性制药企业山东金城医药集团股份有限公司成立合资公司，共同生产并商业化尼古丁口含袋产品。根据协议条款，山东金城医药集团股份有限公司将向合资公司提供生产设备、工艺技术、生产品控体系以及高品质的尼古丁口含袋填充材料，从而使项目几乎能够立即投入运营，从而在短期内实现生产规模和收入的落地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","ISPR","BK0028","BK4075","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116413675","title":"雾麻科技携手金城医药成立战略合资公司，进军高增长尼古丁袋市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1116413675","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116413675?lang=zh_cn&edition=full","pubTime":"2026-05-12 20:32","pubTimestamp":1778589128,"startTime":"0","endTime":"0","summary":"雾麻科技通过一项战略合资协议，正式进军高速增长的尼古丁袋市场。此次合作将联合金城医药的专业能力，共同开拓这一新兴领域。\n合资公司将整合双方优势资源，专注于尼古丁袋产品的研发、制造与市场推广。此举标志着雾麻科技在雾化技术核心业务之外，积极拓展新的增长曲线，以把握全球减害产品市场的结构性机遇。\n尼古丁袋作为一种无烟碱替代产品，近年来在全球范围内呈现显著增长态势，吸引了众多烟草及消费健康企业的布局。通过本次战略合作，双方旨在快速切入这一潜力市场，构建多元化的产品组合，以期在未来竞争中占据有利位置。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300233","BK0028","BK4075","BK0239","ISPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634878294","title":"金城医药(300233)5月10日股东户数2.77万户，较上期减少1.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634878294","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634878294?lang=zh_cn&edition=full","pubTime":"2026-05-12 17:21","pubTimestamp":1778577713,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金城医药披露，截至2026年5月10日公司股东户数为2.77万户，较4月30日减少387.0户，减幅为1.38%。在化学制药行业个股中，金城医药股东户数低于行业平均水平，截至5月10日，化学制药行业平均股东户数为3.58万户。从股价来看，2026年4月30日至2026年5月10日，金城医药区间涨幅为4.45%，在此期间股东户数减少387.0户，减幅为1.38%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200029410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300233","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634202251","title":"金城医药：截至2026年5月10日，公司股东总户数为27,749户","url":"https://stock-news.laohu8.com/highlight/detail?id=2634202251","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634202251?lang=zh_cn&edition=full","pubTime":"2026-05-12 08:36","pubTimestamp":1778546175,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)05月11日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好 截止5月8号 股东人数多少金城医药回复：投资者，您好，截至2026年5月10日，公司股东总户数为27,749户。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200007454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300233","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633570134","title":"金城医药（300233）披露2025年年度权益分派实施公告，5月6日股价上涨2.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633570134","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633570134?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:33","pubTimestamp":1778077996,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，金城医药报收于15.93元，较前一交易日上涨2.64%，最新总市值为61.15亿元。近日，金城医药发布《2025年年度权益分派实施公告》。公告显示，公司2025年年度权益分派方案为：以公司总股本383,874,587股扣除回购专用账户中4,543,000股后的379,331,587股为基数，向全体股东每10股派发现金红利1.5元（含税）。本次实际派发现金红利总额为56,899,738.05元。本次权益分派实施后，按总股本折算的每10股派息为1.482248元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600039952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631555419","title":"金城医药：虾青素申报工作仍处于安全证书认证审评中","url":"https://stock-news.laohu8.com/highlight/detail?id=2631555419","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631555419?lang=zh_cn&edition=full","pubTime":"2026-04-29 09:07","pubTimestamp":1777424876,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)04月28日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司的虾青素项目获得农业转基因生物安全审批书了吗金城医药回复：投资者，您好，虾青素申报工作仍处于安全证书认证审评中，具体需视行政审批部门的审批进度。感谢您的关注！为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260429/32187672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0028","300233","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630335076","title":"股市必读：金城医药一季报 - 第一季度单季净利润同比增长64.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630335076","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630335076?lang=zh_cn&edition=full","pubTime":"2026-04-27 02:57","pubTimestamp":1777229828,"startTime":"0","endTime":"0","summary":"股本股东变化股东户数变动近日金城医药披露，截至2026年4月20日公司股东户数为2.97万户，较4月10日减少1366.0户，减幅为4.39%。公司公告汇总2026年一季度报告金城医药2026年第一季度报告显示，营业收入为750,421,565.86元，同比增长3.95%；归属于上市公司股东的净利润为57,794,502.76元，同比增长64.87%；扣除非经常性损益后的净利润为53,315,937.43元，同比增长61.80%。基本每股收益为0.15元，同比增长66.67%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700005231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629814438","title":"金城医药(300233)4月20日股东户数2.97万户，较上期减少4.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629814438","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629814438?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:38","pubTimestamp":1777023509,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金城医药披露，截至2026年4月20日公司股东户数为2.97万户，较4月10日减少1366.0户，减幅为4.39%。在化学制药行业个股中，金城医药股东户数低于行业平均水平，截至4月20日，化学制药行业平均股东户数为3.51万户。从股价来看，2026年4月10日至2026年4月20日，金城医药区间涨幅为3.37%，在此期间股东户数减少1366.0户，减幅为4.39%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400053332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629084862","title":"金城医药（300233）披露2026年一季度报告，4月23日股价上涨0.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629084862","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629084862?lang=zh_cn&edition=full","pubTime":"2026-04-24 08:16","pubTimestamp":1776989799,"startTime":"0","endTime":"0","summary":"h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}.article_content ul{padding-left:22px;}截至2026年4月23日收盘，金城医药报收于16.06元，较前一交易日上涨0.25%，最新总市值为61.65亿元。该股当日开盘16.01元，最高16.3元，最低15.93元，成交额达1.86亿元，换手率为3.11%。近日，金城医药披露2026年一季度报告。报告显示，公司2026年第一季度营业收入为750,421,565.86元，同比增长3.95%；归属于上市公司股东的净利润为57,794,502.76元，同比增长64.87%；扣除非经常性损益后的净利润为53,315,937.43元，同比增长61.80%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260424/32170305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0028","300233","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629830022","title":"金城医药(300233.SZ)发布一季度业绩，归母净利润5779.45万元，增长64.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629830022","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629830022?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:09","pubTimestamp":1776953388,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金城医药(300233.SZ)发布2026年第一季度报告，该公司营业收入为7.5亿元，同比增长3.95%。归属于上市公司股东的净利润为5779.45万元，同比增长64.87%。归属于上市公司股东的扣除非经常性损益的净利润为5331.59万元，同比增长61.80%。基本每股收益为0.15元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"金城医药(300233.SZ)发布一季度业绩，归母净利润5779.45万元，增长64.87%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629488390","title":"金城医药：截至2026年4月20日，公司股东总户数为29,730户","url":"https://stock-news.laohu8.com/highlight/detail?id=2629488390","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629488390?lang=zh_cn&edition=full","pubTime":"2026-04-23 15:39","pubTimestamp":1776929947,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)04月23日在投资者关系平台上答复投资者关心的问题。投资者提问：秘，你好 截止4月20号 股东人数多少金城医药回复：投资者，您好，截至2026年4月20日，公司股东总户数为29,730户。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300038618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627939342","title":"金城医药：截至2026年4月10日公司股东总户数为31,096户","url":"https://stock-news.laohu8.com/highlight/detail?id=2627939342","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627939342?lang=zh_cn&edition=full","pubTime":"2026-04-16 16:57","pubTimestamp":1776329826,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)04月16日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好 截止4月10号 股东人数多少金城医药回复：投资者，您好，截至2026年4月10日公司股东总户数为31,096户。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600029704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626935761","title":"金城医药最新公告：子公司收到注射用乳糖酸红霉素药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2626935761","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626935761?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:03","pubTimestamp":1775811791,"startTime":"0","endTime":"0","summary":"金城医药公告称，公司控股子公司广东金城金素制药有限公司于近日收到国家药监局下发的注射用乳糖酸红霉素《药品注册证书》，涉及0.25g和0.5g两种规格。此前，公司子公司北京金城泰尔制药有限公司已于2025年获得该原料药上市许可。本次获证实现了公司原料制剂一体化布局，丰富了抗生素类产品管线，有利于提升市场竞争力。鉴于药品销售受政策及市场环境等因素影响，存在不确定性，敬请投资者注意风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000028500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626926455","title":"股市必读：金城医药（300233）预计2026年1-3月扣非后净利润盈利4900万元至5900万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2626926455","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626926455?lang=zh_cn&edition=full","pubTime":"2026-04-09 01:18","pubTimestamp":1775668693,"startTime":"0","endTime":"0","summary":"截至2026年4月8日收盘，金城医药报收于14.8元，上涨2.07%，换手率2.13%，成交量7.89万手，成交额1.16亿元。交易信息汇总资金流向4月8日主力资金净流入650.29万元；游资资金净流入475.52万元；散户资金净流出1125.8万元。金城医药发布业绩预告，预计2026年1-3月归属净利润盈利5300万元至6500万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900001068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625912788","title":"金城医药最新公告：预计一季度归母净利润同比增长51.19%—85.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625912788","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625912788?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:47","pubTimestamp":1775641628,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)披露业绩预告，预计一季度归母净利润5300万元—6500万元，同比增长51.19%—85.42%。报告期内，公司中间体板块部分产品销量较去年同期增加，产能利用率提高。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800027805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624658522","title":"金城医药：截至2026年3月31日，公司股东总户数为28,811户","url":"https://stock-news.laohu8.com/highlight/detail?id=2624658522","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624658522?lang=zh_cn&edition=full","pubTime":"2026-04-03 15:00","pubTimestamp":1775199643,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)04月02日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截至2026年3月 31日公司的股东总数是多少？谢谢金城医药回复：投资者，您好，截至2026年3月31日，公司股东总户数为28,811户。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300023597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300233","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623241313","title":"金城医药（300233）披露董事会专门委员会关于2025年度及换届相关事项的专门意见，3月30日股价下跌1.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623241313","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623241313?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:34","pubTimestamp":1774863263,"startTime":"0","endTime":"0","summary":"截至2026年3月30日收盘，金城医药报收于13.94元，较前一交易日下跌1.83%，最新总市值为53.51亿元。近日，金城医药发布《山东金城医药集团股份有限公司董事会专门委员会关于2025年度及第六届董事会第二十一次会议相关事项的专门意见》公告。公告显示，公司董事会各专门委员会就2025年度报告、续聘2026年度会计师事务所、2025年度内部控制自我评价报告、董事会换届选举及董事候选人任职资格、董事及高管薪酬等事项发表专门意见。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000024180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779521827392,"stockEarnings":[{"period":"1week","weight":-0.0943},{"period":"1month","weight":-0.0925},{"period":"3month","weight":-0.0385},{"period":"6month","weight":-0.0947},{"period":"1year","weight":-0.0735},{"period":"ytd","weight":0.0392}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.0076},{"period":"6month","weight":0.0725},{"period":"1year","weight":0.2168},{"period":"ytd","weight":0.0363}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东金城医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"27749人(较上一季度减少1.38%)","perCapita":"13327股","listingDate":"2011-06-22","address":"山东省淄博市淄川区经济开发区双山路1号","registeredCapital":"38387万元","survey":" 山东金城医药集团股份有限公司的主营业务是医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售。公司的主要产品是硝呋太尔制霉素阴道软胶囊、硝呋太尔胶囊、普罗雌烯乳膏、普罗雌烯氯喹那多阴道片以及注射用头孢唑林钠、注射用头孢他啶、注射用头孢呋辛钠、头孢羟氨苄胶囊、头孢克洛分散片、烟碱、4-AA、4-BMA、EDC、DIC。金城医化、金城汇海通过工信部“绿色工厂”复审，金城医化、金城生物、金城柯瑞通过重点行业绩效分级B级复审。","listedPrice":18.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金城医药(300233)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金城医药,300233,金城医药股票,金城医药股票老虎,金城医药股票老虎国际,金城医药行情,金城医药股票行情,金城医药股价,金城医药股市,金城医药股票价格,金城医药股票交易,金城医药股票购买,金城医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金城医药(300233)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}